Amarin Corp Plc (AMRN)

[Crikker]

I think there will be a window opening for 3 to 6 months starting with the successful ruling in the patent trial. AMRN knows the highest value for the company will be to include Europe and the US to any potential buyer. The company will keep the rights, progress the European drug application and see if an acceptable BO offer comes along.

If they don’t see anything acceptable within 3-6 months after the trial ends they’ll partner with someone to sell into Europe and develop the US themselves. I suspect the GIA might eventually give shareholders the most gain but suspect a buyout at around $60 +/- $10 sometime in the 2nd or 3rd quarter.

It seems that management is gift wrapping the company by de-risking all potential obstacles while growing sales at a near doubling per year.

Surely someone will see a company/product with minimal risk, high sales growth 75% gross margins, $600 million in the bank (not to mention other short term assets such as inventory), and next to no debt as something worth buying.